PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Finan, B. ; Yang, B.* ; Ottaway, N.* ; Smiley, D.L.* ; Ma, T.* ; Clemmensen, C. ; Chabenne, J.* ; Zhang, L.* ; Habegger, K.M.* ; Fischer, K. ; Campbell, J.E.* ; Sandoval, D.A.* ; Seeley, R.J.* ; Bleicher, K.* ; Uhles, S.* ; Riboulet, W.* ; Funk, J.* ; Hertel, C.* ; Belli, S.* ; Sebokova, E.* ; Conde-Knape, K.* ; Konkar, A.* ; Drucker, D.J.* ; Gelfanov, V.* ; Pfluger, P.T. ; Müller, T.D. ; Perez-Tilve, D.* ; DiMarchi, R.D.* ; Tschöp, M.H.

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

J. Nat. Med. 21, 27-36 (2015)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
We report the discovery of a new monomeric peptide that reduces body weight and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple agonist demonstrates supraphysiological potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors. Such balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis in relevant rodent models. Various loss-of-function models, including genetic knockout, pharmacological blockade and selective chemical knockout, confirmed contributions of each constituent activity in vivo. We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity. These preclinical studies suggest that, so far, this unimolecular, polypharmaceutical strategy has potential to be the most effective pharmacological approach to reversing obesity and related metabolic disorders.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
1.593
5.064
330
372
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Controlled-release Phentermine/topiramate; Glp-1 Receptor Activation; Triple-acting Agonist; Fat-fed Mice; Glucagon Receptors; Leptin Responsiveness; Hybrid Peptide; Weight-loss; Glucose; Adults
Sprache englisch
Veröffentlichungsjahr 2015
Prepublished im Jahr 2014
HGF-Berichtsjahr 2014
ISSN (print) / ISBN 1340-3443
e-ISSN 1861-0293
Zeitschrift Journal of natural medicines
Quellenangaben Band: 21, Heft: 1, Seiten: 27-36 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Tokyo [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502200-001
G-501900-221
G-502200-011
PubMed ID 25485909
DOI 10.1038/nm.3761
WOS ID WOS:000348408000010
Erfassungsdatum 2014-12-10
[➜Korrektur melden]